Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby - 2Meet the Stars of the Feline World: Well known Pet Feline Varieties
- 315 Preposterous Cosplay Ensembles That Will Blow You Away
- 4The Best Computer games Ever
- 5Impact of NIH funding reductions felt in cancer and infectious disease trials
- How will the universe end?
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- 4 Famous Attractions at Disneyland
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- Which Switch Game Do You Suggest? Share Your Decision
- Vote in favor of your Favored kind of craftsmanship
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- SUVs Known for Their Looks As opposed to Their Capacity
